Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial

被引：0
|
作者：
Qiuling Zhao
Ruixiang Xie
Wanfu Zhong
Wenbin Liu
Ting Chen
Xiuliang Qiu
Lin Yang
机构：
[1] Clinical Oncology School of Fujian Medical University,Department of Pharmacy
[2] Fujian Cancer Hospital,Department of Pharmacy
[3] Fujian University of Traditional Chinese Medicine,undefined
来源：
Cost Effectiveness and Resource Allocation | / 21卷
关键词：
Durvalumab; PD-L1; Biliary tract cancer; First-line treatment; Cost-effectiveness analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer
    Ying, Jieer
    Xie, Yanru
    Xu, Qi
    Li, Jingjing
    Luo, Cong
    Zhang, Lei
    Wang, Yonghui
    Chen, Li
    Huang, Jianhui
    Li, Wenting
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis
    Zhang, Peng-Fei
    Xie, Dan
    Li, Qiu
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [33] Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).
    Vogel, Arndt
    Chen, Li-Tzong
    He, Aiwu Ruth
    Kim, Jin Won
    Chen, Ming-Huang
    McNamara, Mairead Geraldine
    Shimizu, Satoshi
    Gillmore, Roopinder
    Rey, Felipe
    Kim, Hyosung
    Xiong, Julia
    Makowsky, Mallory
    Rokutanda, Nana
    Cohen, Gordon
    Oh, Do-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer
    Finkelmeier, F.
    Bouattour, M.
    Valle, J. W.
    Vogel, A.
    Kim, J. W.
    Kitano, M.
    Chen, J. -S.
    Burris, H.
    Zaucha, R.
    Qin, S.
    Evesque, L.
    Zhen, D. B.
    Gupta, V. G.
    Park, J. O.
    Zotkiewicz, M.
    Rokutanda, N.
    Cohen, G.
    Oh, D. -Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 127 - 128
  • [35] Cost-Effectiveness Analysis of Monoclonal Antibodies Associated With Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer
    Barufaldi, Laura A.
    de Albuquerque, Rita de C. R.
    do Nascimento, Aline
    Martins, Luis Felipe L.
    Zimmermann, Ivan R.
    de Souza, Mirian C.
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 37 : 33 - 40
  • [36] Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma
    Sampson, FC
    Beard, SM
    Scott, F
    Vandenberghe, E
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) : 1015 - 1019
  • [37] Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinoma-A Cost-Effectiveness Analysis
    Lin, Dong
    Luo, Shaohong
    Lin, Shen
    Zhong, Lixian
    Zhou, Wei
    Gu, Dian
    Huang, Xiaoting
    Chen, Qixin
    Xu, Xiongwei
    Weng, Xiuhua
    CLINICAL GENITOURINARY CANCER, 2022, 21 (01) : 8 - 15
  • [38] Cost-effectiveness analysis of the addition of bevacizumab to first-line chemotherapy in metastatic colorectal cancer
    Villa, D.
    Hedden, L.
    Peacock, S.
    Kennecke, H. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Efficacy and toxicities of adding molecular targeted agents to first-line chemotherapy in the treatment of advanced biliary tract cancer: a systematic review and meta-analysis
    Zhao, Sheng
    Miao, Yanping
    Wang, Ruijun
    Guo, Haidong
    Jin, Feng
    Guo, Xiuling
    Luo, Tianyou
    ONCOTARGETS AND THERAPY, 2016, 9 : 6695 - 6700
  • [40] Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma
    Zhang, Pengfei
    Yang, Yu
    Wen, Feng
    He, Xiaofeng
    Tang, Ruilei
    Du, Zedong
    Zhou, Jing
    Zhang, Jian
    Li, Qiu
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 27 (07) : 853 - 859
12345